Aura Biosciences, Inc. (NASDAQ:AURA) Receives $20.50 Consensus PT from Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $20.50.

A number of equities analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aura Biosciences in a research report on Monday, December 29th. Evercore assumed coverage on shares of Aura Biosciences in a report on Tuesday, November 25th. They set an “outperform” rating on the stock.

Insider Activity at Aura Biosciences

In related news, insider Los Pinos Elisabet De sold 16,928 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $4.86, for a total transaction of $82,270.08. Following the transaction, the insider directly owned 457,463 shares of the company’s stock, valued at $2,223,270.18. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Janet Jill Hopkins sold 17,109 shares of Aura Biosciences stock in a transaction on Monday, November 17th. The shares were sold at an average price of $5.42, for a total value of $92,730.78. Following the completion of the transaction, the insider owned 252,685 shares in the company, valued at $1,369,552.70. This represents a 6.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 35,618 shares of company stock worth $182,685. 6.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aura Biosciences

A number of large investors have recently added to or reduced their stakes in the company. Intech Investment Management LLC lifted its position in shares of Aura Biosciences by 35.9% during the fourth quarter. Intech Investment Management LLC now owns 20,993 shares of the company’s stock valued at $114,000 after buying an additional 5,541 shares during the last quarter. ProShare Advisors LLC bought a new position in shares of Aura Biosciences during the 4th quarter worth approximately $59,000. 49 Wealth Management LLC boosted its stake in Aura Biosciences by 78.9% in the fourth quarter. 49 Wealth Management LLC now owns 18,984 shares of the company’s stock valued at $103,000 after acquiring an additional 8,375 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in Aura Biosciences by 24.5% in the fourth quarter. Harbor Capital Advisors Inc. now owns 32,977 shares of the company’s stock valued at $180,000 after acquiring an additional 6,481 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Aura Biosciences by 12.3% in the third quarter. JPMorgan Chase & Co. now owns 24,557 shares of the company’s stock worth $152,000 after purchasing an additional 2,693 shares during the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Stock Down 2.6%

AURA traded down $0.15 on Thursday, reaching $5.48. 14,350 shares of the company traded hands, compared to its average volume of 180,672. The company has a market cap of $347.66 million, a P/E ratio of -2.84 and a beta of 0.46. Aura Biosciences has a one year low of $4.34 and a one year high of $8.16. The firm has a fifty day simple moving average of $5.67 and a two-hundred day simple moving average of $6.01.

Aura Biosciences (NASDAQ:AURA) last issued its earnings results on Thursday, November 13th. The company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. On average, equities analysts forecast that Aura Biosciences will post -1.66 earnings per share for the current year.

Aura Biosciences Company Profile

Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.